Connection

Antonio Giordano to Drug Resistance, Neoplasm

This is a "connection" page, showing publications Antonio Giordano has written about Drug Resistance, Neoplasm.
Connection Strength

1.315
  1. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. Int J Oncol. 2019 Jun; 54(6):2189-2199.
    View in: PubMed
    Score: 0.568
  2. Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharmacol. 2018 08; 41:59-65.
    View in: PubMed
    Score: 0.531
  3. Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PLoS One. 2019; 14(11):e0224420.
    View in: PubMed
    Score: 0.148
  4. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation. Oncotarget. 2017 Apr 25; 8(17):28939-28958.
    View in: PubMed
    Score: 0.031
  5. The prolyl isomerase Pin1 acts synergistically with CDK2 to regulate the basal activity of estrogen receptor a in breast cancer. PLoS One. 2013; 8(2):e55355.
    View in: PubMed
    Score: 0.023
  6. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer. 2005 12; 12(4):721-47.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.